Abstract
Medulloblastoma (MB) is the most common malignant brain tumor in children and is classified into four molecular subgroups: WNT, SHH, Group 3, and Group 4. Current treatment includes surgical resection, craniospinal irradiation, and chemotherapy. Although these therapies have improved survival rates, they cause severe and long-lasting side effects, highlighting the need for more effective …